Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.

Patients with lupus face a high burden of comorbidities, with the presence of at least one of seven key conditions linked to 55%-60% lower odds of achieving remission or a low disease activity state.

Nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE). Fast Track designation is designed to ...

Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

As treatment strategies evolve in cutaneous lupus erythematosus (CLE), physicians are increasingly turning to advanced systemic therapies while evaluating emerging targeted options that may reshape ...

The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus erythematosus, according to a manufacturer press release. Nipocalimab ...

The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.

Antimitochondrial antibodies can be detected in patients with systemic lupus erythematosus (SLE) and appear prognostic.

A clinical trial in China testing ICP-538, a treatment candidate for MS and other autoimmune diseases, has dosed its first healthy volunteer.

For patients living with Systemic Lupus Erythematosus (SLE), their immune systems mistakenly attack themselves, unleashing dangerous and painful levels of inflammation. For many, the goal is to reach ...

Understanding the type of arthritis, its causes, and management options is the first step toward living well with the condition.

The world is experiencing a hidden epidemic with kidney disease. More than 850 million people worldwide have some form of ...